Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of Micafungin (Mycamin) as Antifungal Prophylaxis Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

Next Previous
Trial Profile

Pharmacokinetics of Micafungin (Mycamin) as Antifungal Prophylaxis Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Micafungin (Primary)
  • Indications Aspergillosis
  • Focus Pharmacokinetics
  • Acronyms MATADOR

Most Recent Events

  • 22 Aug 2018 Results published in the Journal of Antimicrobial Chemotherapy
  • 15 Sep 2016 Status changed from recruiting to completed.
  • 29 Oct 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top